Jens Eckstein of SR One: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Eckstein, President, comes to SR One from TVM Capital where he was a Venture Partner, Entrepreneur-in-Residence and appointed CEO and President of SelectX Pharmaceuticals. Prior to that, he was a General Partner in TVMs Boston life sciences practice where he focused on earlier-stage investments. He is currently a Director of Thrasos Therapeutics, Palleon Pharma, Decibel Therapeutics, Gladius Pharmaceuticals and …

Anders Karlén of Uppsala University: Featured Speaker at World Anti-Microbial Resistance Congress

Anders Karlén, Professor in Computer-aided drug design, Uppsala University, Sweden, is presently the overall medicinal chemistry project leader for drug discovery efforts currently directed at five different anti-bacterial targets at Uppsala University. Several of these projects have been run within EU framework 6 and 7 programmes. Since February 2014 he is the Leader of the Managing Entity and co-coordinator of the …

Jane Knisely of NIH-NIAID: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Jane Knisely is a Program Officer in the Bacteriology and Mycology Branch of the Division of Microbiology and Infectious Diseases at the National Institute of Allergy and Infectious Disease, NIH, where she oversees scientific programs related to antimicrobial resistance and antibacterial drug development. Specifically, Jane is the program officer for NIAID’s Antibacterial Resistance Leadership Group, a clinical trials group focused …

[WHITEPAPER] MDRO Trends Throughout Intermountain Healthcare System

 MDRO Trends Throughout Intermountain Healthcare System  courtesy of OpGen This whitepaper discusses a study conducted by Intermountain Healthcare System and Enterprise Analysis Corporation (EAC) with support from OpGen that examined the trends in MDROs (multidrug resistant organisms) over the 8 year period of 2008-2015. The paper discusses the objectives of the study, which was initiated in December 2015 and concluded …

Steven Gilman of Contrafect Corporation: Featured Speaker of World Anti-Microbial Resistance Congress

Steven Gilman of Contrafect Corporation: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

Dr. Gilman most recently served as the Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist in 2008, Dr. Gilman served as Chairman of the Board of Directors and Chief Executive Officer of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium …

[WHITEPAPER] Quantitative Urine Culture in cUTI Trials: What is the Problem with Genomix? Part 2

Quantitative Urine Culture in cUTI Trials: What is the Problem With Genomix? Part 2 Courtesy of PSI CRO A continuation of an earlier article by the same name, this article builds upon the first, which discussed the challenges and best practices involved in achieving the ideal outcomes when performing quantitative urine culture studies. The second installment goes on to discuss …

[WHITEPAPER] Quantitative Urine Culture in cUTI Trials: What is the Problem With Genomix? Part 1

Quanitative Urine Culture in cUTI Trials: What is the Problem With Genomix? Part 1 courtesy of PSI CRO The first in a two-part article, this whitepaper discusses the challenges and best practices involved in achieving ideal outcomes in quantitative urine culture studies. Download the whitepaper now to learn more about: urine specimen stability quantitative urine culture contamination rates …and more ! …

Evolving existing drug classes to meet the challenges of unmet medical needs: navigating regulatory perspectives

“Evolving existing drug classes to meet the challenge of unmet medical needs: navigating regulatory perspectives “

Mark Jones, PhD, Head of Project Management at Basilea Pharmaceutica joined us for World Anti-Microbial Resistance Congress USA 2015 to discuss ‘navigating regulatory perspectives ‘. In this presentation, learn about navigating regulatory perspectives in the context of the unmet medical need for new antifungals . Download the presentation to understand more about: Where will our new antifungals come from? The …

David Mantus: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

David Mantus of Arsanis: Featured Speaker at World Anti-Microbial Resistance Congress USA 2016

David Mantus, Ph.D. is Chief Development Officer at Arsanis, Inc., a clinical stage biotechnology company developing monoclonal antibodies to prevent and treat serious bacterial infections. He has more than 24 years of drug development experience, including clinical, regulatory and manufacturing successes for programs in endocrinology, central nervous disorders, and infectious disease. His work in infectious disease product development has included …